Traders News Source has released a comprehensive report on MannKind Corporation (NASDAQ:MNKD), a biopharma entity concentrating its efforts on the discovery and development of distinct therapeutic offerings for ailments such as diabetes. The firm’s only approved offering, Afrezza is a rapid-acting inhaled insulin. It is used to regulate high blood sugar in people with type 1 and type 2 diabetes.
Afrezza obtained regulatory approval from the U.S. FDA in June 2014, and has been accessible by prescription in the U.S. since February 2015. The drug relies on MannKind’s Technosphere technology, a proprietary drug delivery platform that enables for the oral inhalation for numerous therapeutics. The Traders News Source last coverage of company, published September 5, 2017, highlighted Afrezza sales after the cancelation of the Sanofi agreement, the firm’s cash reserves and burn rate. Since that report, the shares have jumped over 184% and there are multiple catalysts that cannot be ignored.
Afrezza is used to enhance glycemic control in adult people with diabetes. The product comprises of a dry powder formulation of insulin (human) that is offered by a small portable inhaler. Administered at the start of a meal, Afrezza dissolves fast upon inhalation to the lung and provides insulin fast to the bloodstream, hitting peak insulin levels within just 12 to 15 minutes of administration.
MannKind management expects that its proprietary Technosphere know-how is a candidate for delivery of several drug compounds. The firm is also looking past Afrezza with several other prospective drugs in its pipeline.
In the last trading session, the stock price of MannKind jumped more than 2% to close the day at $5.42. The gains came at a share volume of 10.12 million compared to average share volume of 11.48 million. After the recent gains, the market cap of firm was noted at around $622 million.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.